Clinical trial
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or…
NCT00007865 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00007865 |
|---|---|
| Title | Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Ifosfamide, Carboplatin, and Etoposide (ICE) Chemotherapy in Combination With Rituximab as Salvage Therapy |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, carboplatin, etoposide, ifosfamide |
| Start date | Sep 1, 2000 |
| Primary completion | Mar 1, 2004 |
| Completion | Apr 22, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 27, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: